MedTrace Logo

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-05-08

Study results available
· View outcomes & findings →

Summary

This study tests the hypothesis that extrasynaptic mechanisms are critically linked with cognitive effects of NMDA antagonism as evidenced by event-related potentials (ERPs) in healthy humans.

Conditions

  • Cognitive Dysfunction

Interventions

DRUG

N-acetylcysteine and ketamine

Active drug (N-acetylcysteine)

DRUG

placebo and ketamine

placebo N-acetylcysteine

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Handan Gunduz-Bruce, M.D. · Yale University

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00611897 on ClinicalTrials.gov